Cheng-Jen Ma1,2, Ching-Wen Huang1,3, Yung-Sung Yeh1,4, Hsiang-Lin Tsai1,3, Wei-Chih Su1, Tsung-Kun Chang1, Li-Chu Sun5,6, Ying-Ling Shih5,6, Fang-Jung Yu7,8, Deng-Chyang Wu7,8, Jaw-Yuan Wang9,10,11,12,13,14,15. 1. Division of Colorectal Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, No. 100, Tzyou 1st Road, Kaohsiung, 807, Taiwan. 2. Division of General and Digestive Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan. 3. Department of Surgery, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. 4. Division of Trauma and Surgical Critical Care, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan. 5. Division of Nursing, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan. 6. Nutrition Therapy Team, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan. 7. Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan. 8. Department of Internal Medicine, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. 9. Division of Colorectal Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, No. 100, Tzyou 1st Road, Kaohsiung, 807, Taiwan. cy614112@ms14.hinet.net. 10. Department of Surgery, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. cy614112@ms14.hinet.net. 11. Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. cy614112@ms14.hinet.net. 12. Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. cy614112@ms14.hinet.net. 13. Clinical Pharmacogenomics and Pharmacoproteinomics, College of Pharmacy, Taipei Medical University, Taipei, Taiwan. cy614112@ms14.hinet.net. 14. Cohort Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan. cy614112@ms14.hinet.net. 15. Center for Cancer Research, Kaohsiung Medical University, Kaohsiung, Taiwan. cy614112@ms14.hinet.net.
Abstract
BACKGROUND: Even with significant advances in surgical techniques and treatment, salvage chemotherapy remains the major treatment strategy for patients with unresectable or metastatic gastric cancer (GC). Practical and technical advances have simplified safe and convenient use of supplemental home parenteral nutrition (HPN). We aimed to clarify the role of HPN in patients with incurable GC undergoing salvage chemotherapy. METHODS: We enrolled 25 patients with GC with a nutritional risk index (NRI) of ≦ 97.5 undergoing HPN. Their nutritional status, laboratory data, and quality of life (QoL) were analyzed using the Research and Treatment of Cancer quality of life questionnaire-C30 before and after HPN administration at 0.5, 1, 2, and 3 months. We enrolled 25 patients with an NRI of > 97.5 not undergoing HPN as the control group. RESULTS: Total protein (P = 0.008), prealbumin (P < 0.001), and total cholesterol (P = 0.023) levels improved significantly after 0.5 months of HPN administration. The study group also demonstrated a marked improvement in nitrogen balance (P = 0.004) and prealbumin levels (P < 0.012) after 1 month. Gains in body weight after 1 month and body mass index after 2 months of HPN administration remained comparable with those of the control group. Global QoL scores were maintained and comparable with those of the control group. CONCLUSIONS: Supplemental HPN therapy for malnourished patients with unresectable or metastatic GC undergoing salvage chemotherapy is feasible and revealed marked improvement in nutritional status. Early HPN intervention should be considered an important part of palliative treatment for advanced GC.
BACKGROUND: Even with significant advances in surgical techniques and treatment, salvage chemotherapy remains the major treatment strategy for patients with unresectable or metastatic gastric cancer (GC). Practical and technical advances have simplified safe and convenient use of supplemental home parenteral nutrition (HPN). We aimed to clarify the role of HPN in patients with incurable GC undergoing salvage chemotherapy. METHODS: We enrolled 25 patients with GC with a nutritional risk index (NRI) of ≦ 97.5 undergoing HPN. Their nutritional status, laboratory data, and quality of life (QoL) were analyzed using the Research and Treatment of Cancer quality of life questionnaire-C30 before and after HPN administration at 0.5, 1, 2, and 3 months. We enrolled 25 patients with an NRI of > 97.5 not undergoing HPN as the control group. RESULTS: Total protein (P = 0.008), prealbumin (P < 0.001), and total cholesterol (P = 0.023) levels improved significantly after 0.5 months of HPN administration. The study group also demonstrated a marked improvement in nitrogen balance (P = 0.004) and prealbumin levels (P < 0.012) after 1 month. Gains in body weight after 1 month and body mass index after 2 months of HPN administration remained comparable with those of the control group. Global QoL scores were maintained and comparable with those of the control group. CONCLUSIONS: Supplemental HPN therapy for malnourished patients with unresectable or metastatic GC undergoing salvage chemotherapy is feasible and revealed marked improvement in nutritional status. Early HPN intervention should be considered an important part of palliative treatment for advanced GC.
Entities:
Keywords:
Gastric cancer; Home parenteral nutrition; Malnutrition; Palliative care
Authors: Shlomit Strulov Shachar; Allison M Deal; Marc Weinberg; Grant R Williams; Kirsten A Nyrop; Karteek Popuri; Seul Ki Choi; Hyman B Muss Journal: Clin Cancer Res Date: 2017-01-31 Impact factor: 12.531
Authors: Jann Arends; Patrick Bachmann; Vickie Baracos; Nicole Barthelemy; Hartmut Bertz; Federico Bozzetti; Ken Fearon; Elisabeth Hütterer; Elizabeth Isenring; Stein Kaasa; Zeljko Krznaric; Barry Laird; Maria Larsson; Alessandro Laviano; Stefan Mühlebach; Maurizio Muscaritoli; Line Oldervoll; Paula Ravasco; Tora Solheim; Florian Strasser; Marian de van der Schueren; Jean-Charles Preiser Journal: Clin Nutr Date: 2016-08-06 Impact factor: 7.324
Authors: Christiane Druml; Peter E Ballmer; Wilfred Druml; Frank Oehmichen; Alan Shenkin; Pierre Singer; Peter Soeters; Arved Weimann; Stephan C Bischoff Journal: Clin Nutr Date: 2016-02-16 Impact factor: 7.324
Authors: Carla M M Prado; Vickie E Baracos; Linda J McCargar; Marina Mourtzakis; Karen E Mulder; Tony Reiman; Charles A Butts; Andrew G Scarfe; Michael B Sawyer Journal: Clin Cancer Res Date: 2007-06-01 Impact factor: 12.531
Authors: Carolina Palmela; Sónia Velho; Lisa Agostinho; Francisco Branco; Marta Santos; Maria Pia Costa Santos; Maria Helena Oliveira; João Strecht; Rui Maio; Marília Cravo; Vickie E Baracos Journal: J Gastric Cancer Date: 2017-03-14 Impact factor: 3.720
Authors: P J Ross; S Ashley; A Norton; K Priest; J S Waters; T Eisen; I E Smith; M E R O'Brien Journal: Br J Cancer Date: 2004-05-17 Impact factor: 7.640